Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.

Merali Z, Ross S, Paré G.

Drug Metabol Drug Interact. 2014;29(3):143-51. doi: 10.1515/dmdi-2014-0009. Review.

PMID:
24988246
2.

Effects of alcohol on human carboxylesterase drug metabolism.

Parker RB, Hu ZY, Meibohm B, Laizure SC.

Clin Pharmacokinet. 2015 Jun;54(6):627-38. doi: 10.1007/s40262-014-0226-2.

3.

Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.

Shi J, Wang X, Nguyen JH, Bleske BE, Liang Y, Liu L, Zhu HJ.

Biochem Pharmacol. 2016 Nov 1;119:76-84. doi: 10.1016/j.bcp.2016.09.003. Epub 2016 Sep 8.

4.

Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis.

Laizure SC, Parker RB, Herring VL, Hu ZY.

Drug Metab Dispos. 2014 Feb;42(2):201-6. doi: 10.1124/dmd.113.054353. Epub 2013 Nov 8.

6.

Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2.

Wang J, Williams ET, Bourgea J, Wong YN, Patten CJ.

Drug Metab Dispos. 2011 Aug;39(8):1329-33. doi: 10.1124/dmd.111.039628. Epub 2011 May 3.

7.

Down-regulation of carboxylesterases 1 and 2 plays an important role in prodrug metabolism in immunological liver injury rats.

Zhang C, Xu Y, Gao P, Lu J, Li X, Liu D.

Int Immunopharmacol. 2015 Feb;24(2):153-158. doi: 10.1016/j.intimp.2014.12.003. Epub 2014 Dec 11.

PMID:
25499727
9.

Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages by activated organophosphorus insecticides: role of carboxylesterases 1 and 2.

Xie S, Borazjani A, Hatfield MJ, Edwards CC, Potter PM, Ross MK.

Chem Res Toxicol. 2010 Dec 20;23(12):1890-904. doi: 10.1021/tx1002194.

10.

Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants.

Zhu HJ, Markowitz JS.

Drug Metab Dispos. 2009 Feb;37(2):264-7. doi: 10.1124/dmd.108.024943. Epub 2008 Nov 20.

11.

Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene.

Wu MH, Chen P, Wu X, Liu W, Strom S, Das S, Cook EH Jr, Rosner GL, Dolan ME.

Pharmacogenetics. 2004 Sep;14(9):595-605.

PMID:
15475733
12.

The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.

Lewis JP, Horenstein RB, Ryan K, O'Connell JR, Gibson Q, Mitchell BD, Tanner K, Chai S, Bliden KP, Tantry US, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Gurbel PA, Shuldiner AR.

Pharmacogenet Genomics. 2013 Jan;23(1):1-8. doi: 10.1097/FPC.0b013e32835aa8a2.

13.

Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation.

Zhu HJ, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS.

J Pharmacol Exp Ther. 2013 Mar;344(3):665-72. doi: 10.1124/jpet.112.201640. Epub 2012 Dec 28.

14.

A simple allele-specific polymerase chain reaction method to detect the Gly143Glu polymorphism in the human carboxylesterase 1 gene: importance of genotyping for pharmacogenetic treatment.

Walter Soria N, Belaus A, Galván C, Ana Pasquali M, Velez P, Del Carmen Montes C, Beltramo DM.

Genet Test Mol Biomarkers. 2010 Dec;14(6):749-51. doi: 10.1089/gtmb.2010.0037. Epub 2010 Sep 21.

PMID:
20858053
15.

Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms.

Shi J, Wang X, Eyler RF, Liang Y, Liu L, Mueller BA, Zhu HJ.

Basic Clin Pharmacol Toxicol. 2016 Dec;119(6):555-561. doi: 10.1111/bcpt.12625. Epub 2016 Jul 21.

16.

Opossum carboxylesterases: sequences, phylogeny and evidence for CES gene duplication events predating the marsupial-eutherian common ancestor.

Holmes RS, Chan J, Cox LA, Murphy WJ, VandeBerg JL.

BMC Evol Biol. 2008 Feb 20;8:54. doi: 10.1186/1471-2148-8-54.

17.

Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril.

Zhu HJ, Appel DI, Johnson JA, Chavin KD, Markowitz JS.

Biochem Pharmacol. 2009 Apr 1;77(7):1266-72. doi: 10.1016/j.bcp.2008.12.017. Epub 2009 Jan 6.

PMID:
19185566
18.

Pharmacogenomic assessment of carboxylesterases 1 and 2.

Marsh S, Xiao M, Yu J, Ahluwalia R, Minton M, Freimuth RR, Kwok PY, McLeod HL.

Genomics. 2004 Oct;84(4):661-8.

PMID:
15475243
19.

Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.

Sai K, Saito Y, Tatewaki N, Hosokawa M, Kaniwa N, Nishimaki-Mogami T, Naito M, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Tamura T, Yamada Y, Ohe Y, Yoshida T, Minami H, Ohtsu A, Matsumura Y, Saijo N, Okuda H.

Br J Clin Pharmacol. 2010 Aug;70(2):222-33. doi: 10.1111/j.1365-2125.2010.03695.x.

20.

Impact of endogenous esterase activity on in vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayers.

Ishiguro N, Kishimoto W, Volz A, Ludwig-Schwellinger E, Ebner T, Schaefer O.

Drug Metab Dispos. 2014 Feb;42(2):250-6. doi: 10.1124/dmd.113.053561. Epub 2013 Nov 8.

Supplemental Content

Support Center